

chain nodes :

11 12 15 19 20 21 22 24 25 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

10-11 11-12 12-15 19-25 20-22 20-21 20-26 21-24 25-26 25-27

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10

exact/norm bonds :

2-7 3-10 7-8 8-9 9-10 12-15 19-25 20-22 20-21 21-24 25-27

exact bonds :

10-11 11-12 20-26 25-26

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:N,NH,Hy

G2:CH2,NH,O,SO2,S

G3:H,Ak,Cb

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:CLASS 12:CLASS 15:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 24:CLASS



25:CLASS 26:CLASS 27:Atom

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 N,NH,Hy

G2 CH2,NH,O,SO2,S

G3 H,Ak,Cb

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 16:31:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 205 TO ITERATE

100.0% PROCESSED 205 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3241 TO 4959
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 16:32:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4376 TO ITERATE

100.0% PROCESSED 4376 ITERATIONS 48 ANSWERS
SEARCH TIME: 00.00.01

L3 48 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 16:32:12 ON 18 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2005 VOL 143 ISS 22
FILE LAST UPDATED: 17 Nov 2005 (20051117/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3


L4 1 L3

=> d ibib abs hitstr tot

own work

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:300614 CAPLUS
 DOCUMENT NUMBER: 138:321283
 TITLE: Preparation of benzoxazines as integrin antagonists
 INVENTOR(S): Vianello, Paola; Bandiera, Tiziano
 PATENT ASSIGNEE(S): Pharmacia & Upjohn, S.P.A., Italy
 SOURCE: U.S. Pat. Appl. Publ., 31 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003073688	A1	20030417	US 2001-924709	20010808
US 6750215	B2	20040615		
US 2004224948	A1	20041111	US 2004-821104	20040408
PRIORITY APPLN. INFO.:			US 2001-924709	A1 20010808
OTHER SOURCE(S):				
GI				



AB Title compds. [I; g = Q'NHC(Q)NH, Q1, Q2, Q3, etc.; Q = NH, O; Q' = H alkyl, Ph, phenylalkyl; R3 = H, alkyl; B = (CH2)m(CH:CH)pY; m = 1-3; p = 0, 1; Y = CH2, CO; R = H, alkyl, alkenyl, alkynyl, aryl, aralkyl; R1 = H, alkyl, alkoxy, OH, halo, CF3; R2 = alkyl, alkenyl, alkynyl, aryl, (substituted) heteroaryl; A = CH2, NH, O, S, SO, SO2, were prepared Thus, 7-nitro-3-oxo-3,4-dihydro-2H-1,4-benzoxazine (preparation given) in THF/DMF

at 0° was treated with potassium hexamethyldisilazide and then with 3-[N-benzoyloxycarbonyl-N-(1-oxido-2-pyridinyl)amino]propyl methanesulfonate in THF followed by heating at 80° for 3 h to give 34% 7-nitro-4-[3-(N-benzoyloxycarbonyl-N-(1-oxido-2-pyridinyl)amino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazine. This was stirred with TiCl4 and SnCl2 in THF/EtOH for 6 h at 40° to give 70% 7-amino-4-[3-(N-benzoyloxycarbonyl-N-(2-pyridinyl)amino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazine. The latter was converted in several steps to title compound N-[3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl]-3-phenyl-L-alanine (II). II bound to $\alpha v \beta 3$ vitronectin receptors with IC50 = 0.011 μ M. A II capsule formulation is given.

IT 511544-45-9P 511544-47-1P 511544-50-6P

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


511544-52-8P 511544-54-0P 511544-56-2P
 511544-58-4P 511544-60-8P 511544-62-0P
 511544-65-3P 511544-68-6P 511544-71-1P
 511544-72-2P 511544-74-4P 511544-78-0P
 511544-80-2P 511544-82-4P 511544-84-6P
 511544-86-8P 511544-88-0P 511544-89-1P
 511544-92-6P 511544-95-9P 511544-98-2P
 511545-01-0P 511545-03-2P 511545-06-5P
 511545-09-8P 511545-11-2P 511545-14-5P
 511545-16-7P 511545-19-0P 511545-23-6P
 511545-25-8P 511545-27-0P 511545-29-2P
 511545-31-6P 511545-33-8P 511545-35-0P
 511545-37-2P 511545-39-4P 511545-40-7P
 511545-42-9P 511545-44-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN (prepn. of benzoxazines as integrin antagonists)

RN 511544-45-9 CAPLUS


CN Benzenepropanoic acid, β -[3,4-dihydro-4-[2-(2-pyridinylamino)ethyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 511544-47-1 CAPLUS


CN Benzenepropanoic acid, β -[3,4-dihydro-4-[3-(2-pyridinylamino)propyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 511544-50-6 CAPLUS

CN Benzenepropanoic acid, β -[3,4-dihydro-4-[4-(2-pyridinylamino)butyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 511544-52-8 CAPLUS

CN Benzenepropanoic acid, β -[3,4-dihydro-4-[2-(1H-imidazol-2-ylamino)ethyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-54-0 CAPLUS

CN Benzenepropanoic acid, β -[3,4-dihydro-4-[3-(1H-imidazol-2-ylamino)propyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)


<11/18/2005>

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 511544-56-2 CAPLUS

CN Benzenepropanoic acid, β -[3,4-dihydro-4-[4-(1H-imidazol-2-ylamino)butyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 511544-58-4 CAPLUS


CN 3-Pyridinepropanoic acid, β -[3,4-dihydro-4-[2-(2-pyridinylamino)ethyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-60-8 CAPLUS

Hahte

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[3-(2-pyridinylamino)propyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-62-0 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[4-(2-pyridinylamino)butyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-65-3 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[2-(1H-imidazol-2-ylamino)ethyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 511544-72-2 CAPLUS
 CN Benzenepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[2-(2-pyridinylamino)ethyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-74-4 CAPLUS
 CN Benzenepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[3-(2-pyridinylamino)propyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-78-8 CAPLUS
 CN Benzenepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[4-(2-pyridinylamino)butyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 511544-68-6 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[3-(1H-imidazol-2-ylamino)propyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-71-1 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[4-(1H-imidazol-2-ylamino)butyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 511544-80-2 CAPLUS
 CN Benzenepropanoic acid, β -[[[3,4-dihydro-4-[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-82-4 CAPLUS
 CN Benzenepropanoic acid, β -[[[3,4-dihydro-4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-84-6 CAPLUS
 CN Benzenepropanoic acid, β -[[[3,4-dihydro-4-[4-(1H-imidazol-2-

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ylamino)butyl]-3-oxo-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-86-8 CAPLUS
CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[[2-(2-pyridinylamino)ethyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-88-0 CAPLUS
CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[[3-(2-pyridinylamino)propyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 511544-95-9 CAPLUS
CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-98-2 CAPLUS
CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511545-01-0 CAPLUS
CN Benzenepropanoic acid, β -[[[3,4-dihydro-4-[[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-2H-1,4-benzoxazin-7-yl]oxy]- (9CI) (CA INDEX NAME)

<11/18/2005>

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 511544-89-1 CAPLUS
CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[[4-(2-pyridinylamino)butyl]-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 511544-92-6 CAPLUS
CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-2H-1,4-benzoxazin-7-yl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 511545-03-2 CAPLUS
CN Benzenepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[[4-(2-pyridinylamino)butyl]-2H-1,4-benzoxazin-7-yl]oxy]- (9CI) (CA INDEX NAME)




RN 511545-06-5 CAPLUS
CN Benzenepropanoic acid, β -[[[3,4-dihydro-4-[[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-2H-1,4-benzoxazin-7-yl]oxy]- (9CI) (CA INDEX NAME)




RN 511545-09-8 CAPLUS
CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[[3-(2-pyridinylamino)propyl]-3-oxo-2H-1,4-benzoxazin-7-yl]oxy]- (9CI) (CA INDEX NAME)

Hahte


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 511545-11-2 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[(2-pyridinylamino)butyl]-2H-1,4-benzoxazin-7-yl]oxy]- (9CI) (CA INDEX NAME)




RN 511545-14-5 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-2H-1,4-benzoxazin-7-yl]thio]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 511545-25-8 CAPLUS
 CN Benzenepropanoic acid, β -[[[3,4-dihydro-4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-2H-1,4-benzoxazin-7-yl]thio]- (9CI) (CA INDEX NAME)




RN 511545-27-0 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[3-(2-pyridinylamino)propyl]-2H-1,4-benzoxazin-7-yl]thio]- (9CI) (CA INDEX NAME)




RN 511545-29-2 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[(2-pyridinylamino)butyl]-2H-1,4-benzoxazin-7-yl]thio]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 511545-16-7 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-2H-1,4-benzoxazin-7-yl]oxy]- (9CI) (CA INDEX NAME)




RN 511545-19-0 CAPLUS
 CN Benzenepropanoic acid, β -[[[3,4-dihydro-3-oxo-4-[(2-pyridinylamino)butyl]-2H-1,4-benzoxazin-7-yl]thio]- (9CI) (CA INDEX NAME)




RN 511545-23-6 CAPLUS
 CN Benzenepropanoic acid, β -[[[3,4-dihydro-4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-2H-1,4-benzoxazin-7-yl]thio]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 511545-31-6 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-2H-1,4-benzoxazin-7-yl]thio]- (9CI) (CA INDEX NAME)



RN 511545-33-8 CAPLUS
 CN 3-Pyridinepropanoic acid, β -[[[3,4-dihydro-4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-2H-1,4-benzoxazin-7-yl]thio]- (9CI) (CA INDEX NAME)




RN 511545-35-0 CAPLUS
 CN 2H-1,4-Benzoxazine-7-butanoic acid, 3,4-dihydro-3-oxo-beta-phenyl-4-[4-(2-pyridinylamino)butyl]- (9CI) (CA INDEX NAME)


<11/18/2005>

Habte


L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 511545-37-2 CAPLUS
 CN 2H-1,4-Benzoxazine-7-butanoic acid, 3,4-dihydro-4-([3-(1H-imidazol-2-ylamino)propyl]-3-oxo-β-phenyl)- (9CI) (CA INDEX NAME)




RN 511545-39-4 CAPLUS
 CN 2H-1,4-Benzoxazine-7-butanoic acid, 3,4-dihydro-4-([4-(1H-imidazol-2-ylamino)butyl]-3-oxo-β-phenyl)- (9CI) (CA INDEX NAME)




RN 511545-40-7 CAPLUS
 CN 2H-1,4-Benzoxazine-7-butanoic acid, 3,4-dihydro-3-oxo-β-3-pyridinyl-4-

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 [4-(2-pyridinylamino)butyl]- (9CI) (CA INDEX NAME)

RN 511545-42-9 CAPLUS
 CN 2H-1,4-Benzoxazine-7-butanoic acid, 3,4-dihydro-4-([3-(1H-imidazol-2-ylamino)propyl]-3-oxo-β-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 511545-44-1 CAPLUS
 CN 2H-1,4-Benzoxazine-7-butanoic acid, 3,4-dihydro-4-([4-(1H-imidazol-2-ylamino)butyl]-3-oxo-β-3-pyridinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT 511545-54-3P 511545-56-5P 511545-57-6P
 511545-58-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of benzoxazines as integrin antagonists)
 RN 511545-54-3 CAPLUS
 CN Benzenepropanoic acid, β-([3,4-dihydro-3-oxo-4-([3-
 [(phenylmethoxy)carbonyl]-2-pyridinylamino)propyl]-2H-1,4-benzoxazin-7-
 yl]amino)-, ethyl ester (9CI) (CA INDEX NAME)




RN 511545-56-5 CAPLUS
 CN Benzenepropanoic acid, β-([3,4-dihydro-3-oxo-4-([3-(2-
 pyridinylamino)propyl]-2H-1,4-benzoxazin-7-yl]amino)-, ethyl ester (9CI)
 (CA INDEX NAME)




RN 511545-57-6 CAPLUS
 CN Benzenepropanoic acid, β-([3,4-dihydro-4-([3-
 [(phenylmethoxy)carbonyl]-2-pyridinylamino)propyl]-2H-1,4-benzoxazin-7-
 yl]amino)-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 511545-58-7 CAPLUS
 CN Benzenepropanoic acid, β-([3,4-dihydro-4-([3-(2-pyridinylamino)propyl]-
 2H-1,4-benzoxazin-7-yl]amino)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT